JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
JCR Pharmaceuticals Co., Ltd. announced today that the first patient in the Phase I/II clinical trial with Mucopolysaccharidosis Type IIIA has been dosed with JR‑441, a blood-brain barrier ...
Nordrhein Westfalen United States Nicole Muschol Shin Ashida Pharmaceuticals Co Ltd University Hospital Of Hamburg Eppendorf
Source: marketscreener.com